Homoeopathy in preventing Influenza like Illness

Efficacy of Homoeopathic intervention Influenzinum 30 in preventing Influenza-like Illness (ILI) at urban slums of Delhi - cluster-randomized, double-blind, placebo-control trial. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099257

Enrollment

10000

Registered

2025-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Influenzinum 30: 02 pills in each dose of the Influenzinum 30, to be given per week from January to March for children. 04 pills in each dose of the Influenzinum 30, to be given per wee

Eligibility

Inclusion criteria

Inclusion criteria: Voluntary written informed consent by the family head.

Exclusion criteria

Exclusion criteria: Pregnant women and lactating mother Infants below age of 1 year Individuals taking other preventive medicines for ILI. Patients with malignancy, immunocompromised state, life threatening diseases, end stage diseases. Symptoms of acute febrile illness/ influenza like illness at the time of enrolment. Patient with symptoms of acute infectious illnesses at the time of enrolment. Not willing to give written informed consent.

Design outcomes

Primary

Measure	Time frame
Incidence of Influenza-like Illness between the groupsTimepoint: Baseline, 1 week, 2 week, 3 week, 4 week, 5 week, 6 week, 7 week, 8 week, 9 week, 10 week, 11 week, 12 week, 13 week, 14 week, 15 week, 16 week	—

Secondary

Measure	Time frame
Incidence of AUFI between the groupsTimepoint: Baseline, 1 week, 2 week, 3 week, 4 week, 5 week, 6 week, 7 week, 8 week, 9 week, 10 week, 11 week, 12 week, 13 week, 14 week, 15 week, 16 week;Changes in severity of symptoms between the groups during post prophylactic/ climatic infectionsTimepoint: 12 Weeks;Mean duration of acute febrile illnesses between the cohortsTimepoint: 16 week	—

Countries

India

Contacts

Public ContactDr Debadatta Nayak

Central Council for Research in Homoeopathy

drdnayak@gmail.com9873040412

Outcome results